By rray, 12 July, 2024 Assess tx for efficacy and onset of side effects w in 4 8wk of tx initiation EO nbsp nbsp If intolerable side effects or inadequate improvement May offer a different medication in the same class or a medication from a different class CP For pts on antimus
By rray, 12 July, 2024 Don t use antimuscarinics if narrow angle glaucoma unless approved by pt s ophthalmologist use w extreme caution if impaired gastric emptying or urinary retention hx CP if PVR 250 300 mL use w caution If obstructive voiding sx appear monitor PVR
By rray, 12 July, 2024 Discuss potential risk for dementia and cognitive impairment w pts taking or prescribed antimuscarinics CP
By rray, 12 July, 2024 Choose tx based on side effect profile in the context of shared decision making CP nbsp nbsp Antimuscarinics common dry mouth constipation voiding dysfunction incomplete emptying retention blurred vision rare palpitations tachycardia and QT prolongation w
By rray, 12 July, 2024 Offer oral antimuscarinics darifenacin fesoterodine oxybutynin solifenacin tolterodine trospium or 3 adrenoceptor agonists mirabegron vibegron SR A Transdermal oxybutynin patch Oxytrol males only Rx and Oxytrol for Women OTC may be offered R C
By rray, 12 July, 2024 May offer select noninvasive therapies to all pts w OAB CP nbsp nbsp PFMT e g urge suppression muscle strengthening nbsp nbsp Magnetic stimulation nbsp nbsp Transcutaneous electrical stimulation nbsp nbsp TTNS nbsp nbsp Transvaginal electrical stimulation
By rray, 12 July, 2024 May combine or change therapies if the pt nbsp nbsp Is unwilling or unable to undergo certain therapies nbsp nbsp Has intolerable side effects nbsp nbsp Doesn t have adequate sx improvement
By rray, 12 July, 2024 Telemedicine may be offered for initial eval w the understanding that a physical exam won t be performed and to obtain UA at a lab or review recent lab results EO
By rray, 12 July, 2024 Assess for comorbid conditions that may contribute to urinary frequency urgency or UUI and educate pts on how managing them can affect bladder sx EO nbsp nbsp Comorbid conditions include obesity constipation pelvic organ prolapse genitourinary syndrome of